Acasă › Melanom › Massachusetts › Boston
Studii clinice pentru Melanom în Boston, MA
26 studii pentru Melanom caută participanți în și în jurul orașului Boston (în aproximativ 50 km). Deschideți un studiu pentru a vedea criteriile de eligibilitate și cum să contactați echipa de cercetare.
Text oficial al studiului (în engleză)
Phase 1/2 Study of Intravenous Injection of STX-003 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab
În curs de recrutareFaza 1/2
- Massachusetts General Hospital, Boston
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
În curs de recrutareFaza 1/2
- Tufts Medical Center, Boston
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
În curs de recrutareFaza 2
- Local Institution - 0124, Boston
DOC1021 Dendritic Cell Immunotherapy for Refractory Melanoma
În curs de recrutareFaza 1/2
- Massachusetts General Hospital Cancer Institute, Boston
Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases
În curs de recrutareFaza 2
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
În curs de recrutareFaza 1/2
- Dana Farber Cancer Institute, Boston
- Massachusetts General Hospital, Boston
Cryoablation+Ipilimumab+Nivolumab in Melanoma
În curs de recrutareFaza 2
- Massachusetts General Hospital Cancer Center, Boston
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
În curs de recrutareFaza 1/2
- Dana-Farber Cancer Institute, Boston
Project: Every Child for Younger Patients With Cancer
În curs de recrutareStudiu observațional
- Massachusetts General Hospital Cancer Center, Boston
- Dana-Farber Cancer Institute, Boston
Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors
În curs de recrutareFaza 1/2
- Massachusetts General Hospital, Boston
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
În curs de recrutareFaza 1/2
- Massachusetts General Hospital Cancer Center, Boston
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
În curs de recrutareFaza 1
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
În curs de recrutareFaza 1/2
- Call for Information (Investigational Site 0026), Boston
Video Education With Result Dependent dIsclosure
În curs de recrutare
- Dana Farber Cancer Institute, Boston
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
În curs de recrutareFaza 1/2
- Dana Farber Cancer Institute, Boston
ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
În curs de recrutareFaza 1/2
- Massachusetts General Hospital, Boston
Neoadjuvant Darovasertib in Primary Uveal Melanoma
În curs de recrutareFaza 3
- Massachusetts General Hospital, Boston
A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma
În curs de recrutareFaza 2/3
- Dana Farber, Boston
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
În curs de recrutareFaza 2/3
- Massachusetts General Hospital, Boston
Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
În curs de recrutareFaza 3
- Massachusetts General Hospital, Boston
- Beth Israel Deaconess Medical Center (BIDMC), Boston
- Dana Farber Cancer Institute, Boston
ACTengine® IMA203 Combined With mRNA-4203
În curs de recrutareFaza 1
- Dana Farber Cancer Institute, Boston
Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma
În curs de recrutareFaza 2
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
În curs de recrutareFaza 1/2
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
În curs de recrutareFaza 1/2
- Massachusetts General Hospital, Boston
Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
În curs de recrutareFaza 1/2
- Massachusetts General Hospital, Boston
Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors
În curs de recrutareFaza 2
- Dana Farber Cancer Institute, Boston
Studii pentru Melanom în alte orașe
- Houston, TX59 studii
- New York City, NY38 studii
- Los Angeles, CA34 studii
- Nashville, TN33 studii
- Pittsburgh, PA31 studii
- Philadelphia, PA23 studii
- San Francisco, CA22 studii
- Durham, NC21 studii
- Atlanta, GA21 studii
- St. Louis, MO21 studii
- Salt Lake City, UT21 studii
- Columbus, OH21 studii
Alte studii în Boston
- Cancer de sân111 studii
- Cancer pulmonar cu celule non-pătrate90 studii
- Cancer (toate tipurile)86 studii
- Cancer colorectal63 studii
- Cancer metastatic63 studii
- Cancer pulmonar62 studii
- Cancer ovarian61 studii
- Cancer de prostată59 studii
- Depresie52 studii
- Cancer endometrial50 studii
- Insuficiență cardiacă44 studii
- Leucemie mieloasă acută44 studii
Sursă: ClinicalTrials.gov, date preluate la 5 oct. 2026. Fiecare studiu are propriile criterii de eligibilitate; echipa de cercetare decide cine poate participa.